StockData
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

ADMA BIOLOGICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$11.07+0.39 (+3.65%)

Close on Oct 19, 2026

Market cap
$2.55B
P/E (TTM)
15.8
Dividend yield
–

Adma Biologics statistics

Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison

Valuation

MeasureAdma BiologicsIndustry median
Market Cap$2.48B$164.85M
Enterprise Value$2.54B$87.06M
PE Ratio15.8119.63
PS Ratio4.843.60
PB Ratio6.072.03
P/TBV Ratio6.142.31
P/FCF Ratio21.2917.44
P/OCF Ratio18.1413.32

Enterprise value

MeasureAdma BiologicsIndustry median
EV / Sales4.962.43
EV / EBITDA10.9514.69
EV / EBIT11.3218.47
EV / FCF21.8120.97

Income (trailing twelve months)

MeasureAdma BiologicsIndustry median
Revenue$512.28M$57.94M
Gross Profit$331.47M$90.47M
Operating Income$224.48M-$21.44M
Pretax Income$216.47M-$14.45M
Net Income$168.96M-$22.46M
EBITDA$231.98M-$16.91M
EPS (Diluted)$0.70-$0.83

Margins

MeasureAdma BiologicsIndustry median
Gross Margin64.7%52.3%
Operating Margin43.8%-44.5%
Pretax Margin42.3%-13.0%
Profit Margin33.0%-39.2%
EBITDA Margin45.3%-31.3%
FCF Margin22.7%-8.85%

Returns

MeasureAdma BiologicsIndustry median
Return on Equity (ROE)41.9%-53.1%
Return on Assets (ROA)27.2%-41.0%
Return on Invested Capital (ROIC)45.1%-32.0%
Return on Capital Employed (ROCE)36.9%-37.8%

Growth

MeasureAdma BiologicsIndustry median
Revenue Growth (YoY)8.04%6.01%
Net Income Growth (YoY)-19.1%-37.7%
EPS Growth (YoY)-17.6%-29.2%
FCF Growth (YoY)77.1%2.34%
Revenue Growth (3Y CAGR)49.0%2.25%
Revenue Growth (5Y CAGR)64.6%6.42%

Balance sheet

MeasureAdma BiologicsIndustry median
Cash & Short-Term Investments$136.02M$62.42M
Total Debt$196.59M$120.13M
Net Cash (Debt)-$60.57M$15.68M
Net Cash Per Share-$0.27$0.66
Equity (Book Value)$408.21M$48.79M
Book Value Per Share$1.82$1.36
Tangible Book Value$404.10M$23.06M
Working Capital$452.45M$75.77M

Financial position

MeasureAdma BiologicsIndustry median
Current Ratio6.973.30
Quick Ratio3.622.39
Debt / Equity0.480.51
Debt / EBITDA0.853.35
Debt / FCF1.695.05
Net Debt / EBITDA0.262.22
Interest Coverage25.44-7.12

Cash flow (trailing twelve months)

MeasureAdma BiologicsIndustry median
Operating Cash Flow$136.72M-$12.35M
Capital Expenditures-$20.25M-$1.06M
Free Cash Flow$116.47M-$20.28M
FCF Per Share$0.52-$0.42

Efficiency

MeasureAdma BiologicsIndustry median
Asset Turnover0.820.38
Inventory Turnover0.842.67
Revenue Per Employee$791.77K$398.96K
Profits Per Employee$261.14K-$703.34K
Employee Count64774

Dividends and yields

MeasureAdma BiologicsIndustry median
Earnings Yield6.81%-22.7%
FCF Yield4.70%-9.07%
Buyback Yield7.55%-0.73%
Shareholder Yield7.55%0.00%

Shares

MeasureAdma BiologicsIndustry median
Shares Outstanding223,985,00058,179,650
Shares Change (YoY)-2.84%11.1%
Shares Change (QoQ)-2.98%0.54%
Float217,262,00049,173,100
Shares Held by Insiders3.00%11.6%
Shares Held by Institutions91.8%59.4%

Taxes

MeasureAdma BiologicsIndustry median
Income Tax$47.52M$91.50K
Effective Tax Rate22.0%20.6%

Scores

MeasureAdma BiologicsIndustry median
Graham Number$5.36$17.36
Graham Upside-51.6%-43.6%
Altman Z-Score7.85-0.24
Piotroski F-Score54
Beneish M-Score-0.18-2.62

Calculated by StockData from Adma Biologics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.